Cooperative clinical trial of photodynamic therapy with photofrin II and excimer dye laser for early gastric cancer

Mimura, Seishiro; Ito, Yoshiaki; Nagayo, Takeo; Ichii, Makoto; Kato, Harubumi; Sakai, Harumasa; Gotō, Kazuo; Noguchi, Yasuki; Tanimura, Hiroshi; Nagai, Yugo; Suzuki, Shigeru; Hiki, Yoshiki; Hayata, Yoshihiro

doi:10.1002/(sici)1096-9101(1996)19:2<168::aid-lsm7>3.3.co;2-1

Cited by 21 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent studies have applied this therapy to early and advanced cancer treatments [12,19,20]. Many types of photosensitizers, which are considered important, in this therapy have been synthesized, but these agents have limitations such as water solubility and side effects in vivo.…”

Section: Discussionmentioning

confidence: 99%

Photodynamic therapy for human oral squamous cell carcinoma and xenografts using a new photosensitizer, PAD‐S31

Date

Sakata²,

Fukuchi

et al. 2003

Lasers Surg Med

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Photodynamic therapy for human oral squamous cell carcinoma and xenografts using a new photosensitizer, PAD‐S31

Date

Sakata²,

Fukuchi

et al. 2003

Lasers Surg Med

View full text Add to dashboard Cite

show abstract

“…3 The laser equipment employed was model PDT EDL-1 from Hamamatsu Photonics K.K.. This laser system consists of an excimer laser which emits a pulsed laser beam coupled to a dye laser.…”

Section: Laser Equipmentmentioning

confidence: 99%

“…The main ingredient is dihematoporphyrin ether/ester. PHE was manufactured by Quadra Logic Technology (QLT), Vancouver, Canada, and provided by Lederle (Japan) Co., Ltd. 3 After injection of PHE, the patients are instructed to avoid strong light for at least four weeks.…”

Section: Photosensitizermentioning

confidence: 99%

“…5 Before photosensitization, the irradiated area was marked by metal clips which was set the entire lesion plus about 5mm width of marginal mucosa. 3 This procedure was performed to avoid misleading of the irradiated area due to a lot of mucus and severe edema produced immediately after the beginning of laser irradiation. Patients were intravenously administered 2.0 mg/kg of Photofrin after 75mg/vial of Photofrin dissolved with 30 ml of 5% glucose.…”

Section: Pdt Proceduresmentioning

confidence: 99%

See 1 more Smart Citation

Photofrin-PDT for gastric cancer in the era of endoscopic submucosal dissection

et al. 2009

View full text Add to dashboard Cite

Background: Endoscopic mucosal resection (EMR) was originated to treat early gastric cancer (EGC). EMR was suitable for small, mucosal and well-differentiated adenocarcinoma without ulceration. It was difficult to resect larger tumors en bloc by this method. In recent years, a more useful method, endoscopic submuscosal dissection (ESD) has been developed, which enables en bloc resection of large mucosal lesions. On the contrary, photodynamic therapy (PDT) is applicable to submucosal, poorly differentiated, or carcinoma with ulceration. In the era of ESD, we evaluated the value of Photofrin-PDT. Patients & Methods: We applied PDT to 36 patients including three advanced cancers, who had been excluded from EMR (ESD) and were at high risks for surgery or refused surgery. Four EGC patients who had not been cured by EMR (ESD) were included. Our PDT procedure consisted of polyhematoporphyrin ether/ester administration (Photofrin, 2 mg/Kg) and pulsed excimer dye laser irradiation at 630 nm 48 hours (and 96 hours) after sensitization. Results: Complete response (CR) at three months was obtained in 84% (21/25) of mucosal cancer and in 50% (4/8) of submucosal cancer. Although three patients with an advanced cancer improved but were not cured, quality of their life was maintained. There were no serious side effects except skin photosensitivity. Conclusion: Photofrin-PDT should be applied not only EGC patients who are excluded from ESD and have not been cured by ESD with poor risk for surgery, and have high possibilitiy to be cured by PDT, but also advanced cancer patients for local improvement of lesions.

show abstract

“…[27][28][29][30][31][32][33][34] Imaging with far-red and near-infrared absorbing and emitting dyes such as cyanine, squaraine, thiazine, oxazine, porphyrins, and phthalocyanines, is commmonplace and most of them have been approved for clinical trials. [35][36][37][38][39][40][41][42][43][44][45][46][47] Recently, a new class of dyes, borondipyrromethane (BODIPY) derivatives, have emerged and gained popularity. [48][49][50][51][52][53] However, imaging with small molecules have some challenges in both their optical performance and delivery to the tissue of interest, such as water insolubility, aggregation, low quantum yield, insufficient photostability, low tumor to background ratio, and short in vivo circulation lifetimes.…”

Section: Small Molecule Imagingmentioning

confidence: 99%

Mini-review: fluorescence imaging in cancer cells using dye-doped nanoparticles

2016

View full text Add to dashboard Cite

Fluorescence imaging has gained increased attention over the past two decades as a viable means to detect a variety of cancers. Fluorescence imaging has the potential to provide physicians with high resolution images with enhanced contrast, which will allow them to be able to better diagnose and treat patients with cancer. Early detection and treatment are key to erradicating cancer in a patient, and fluorescence imaging has the ability to identify non-advanced, even pre-cancerous, tumors where imaging based on white light or radiation overlooked them. Several fluorescent dyes have been identified as possible fluorophores for enhanced fluorescence imaging, such as cyanine, squaraine, porphyrin, phthalocyanine, and borondipyrromethane dyes. These dyes have high fluorescence quantum yields, which provides a high target to background ratio; however, these dyes are often plagued by low water solubility. This low solubility can be ameliorated by conjugating or covalently attaching these dyes to polymeric crosslinked micelles, polymersomes, or polymer-core nanoparticles. These particle & dye systems then can become platforms on which secondary components can be attached to enhance the systems functionality. For example, dyes attached to these nanocarriers can target tumors through passive targeting; however, active targeting can be achieved by further modifying these nanocarriers with ligands that have a binding affinity for receptors overexpressed in tumor cells, cell surface receptors located on the tumor cell membrane, or endothelium. Fluorescence activation of the probes is another promising technology for the early detection of cancer. Activation requires that there be a change in fluorescence, whether it be an emission wavelength change or a fluorescence "on/off" signal when in the presence of some external stimuli. Activation increase the target to background ratio and enhances the contrast of the obtained image. This review serves to highlight the recent developments of (1) improved fluorescent dyes for the detection of cancer, with a specific focus on dyes that are being coupled to nanocarriers; (2) dye & nanocarrier systems that target, both actively and passively, tumors, and (3) fluorescence activation of these fluorophore systems for better image quality.

show abstract

Cooperative clinical trial of photodynamic therapy with photofrin II and excimer dye laser for early gastric cancer

Cited by 21 publications

References 0 publications

Photodynamic therapy for human oral squamous cell carcinoma and xenografts using a new photosensitizer, PAD‐S31

Photodynamic therapy for human oral squamous cell carcinoma and xenografts using a new photosensitizer, PAD‐S31

Photofrin-PDT for gastric cancer in the era of endoscopic submucosal dissection

Mini-review: fluorescence imaging in cancer cells using dye-doped nanoparticles

Contact Info

Product

Resources

About